OBGC
IART icon

O'Brien Greene & Co’s Integra LifeSciences IART Stock Holding History

O'Brien Greene & Co’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,100
Closed -$410K – 112
2018
Q4 		$410K Buy
+9,100
New +$499K 0.24% 74

Other funds holding IART

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

O'Brien Greene & Co's IART Position: Q1 2019 in Review

O'Brien Greene & Co sold out of Integra LifeSciences (IART) in Q1 2019, closing a stake of 9,100 shares — an estimated $410K sold.

O'Brien Greene & Co first reported a position in IART in Q4 2018 and held it in 1 quarter. The position peaked at $410K in Q4 2018. 259 funds tracked by Wall St. Rank hold IART as of Q1 2019.

  • O'Brien Greene & Co reported no remaining Integra LifeSciences position as of Q1 2019 after selling out during the quarter.
  • O'Brien Greene & Co sold 9,100 Integra LifeSciences shares in Q1 2019, an estimated $410K.
  • O'Brien Greene & Co first reported a position in Integra LifeSciences in Q4 2018 and held it in 1 quarter.
  • O'Brien Greene & Co's Integra LifeSciences position peaked at $410K in Q4 2018.
  • 259 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2019.

Based on O'Brien Greene & Co's 13F filing for Q1 2019, filed 29 Apr 2019.